Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from ArriVent BioPharma, Inc. ( (AVBP) ) is now available.
On June 23, 2025, ArriVent BioPharma announced positive interim data from its global Phase 1b study of firmonertinib monotherapy for non-small cell lung cancer (NSCLC) with EGFR PACC mutations. The study showed promising results, including a median progression-free survival of 16 months and significant tumor size reduction in patients. The treatment was well-tolerated, with no severe adverse events leading to discontinuation. Based on these findings, ArriVent plans to initiate a global Phase 3 study, ALPACCA, in the second half of 2025, aiming for accelerated approval and addressing the unmet needs of patients with PACC mutations.
The most recent analyst rating on (AVBP) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on ArriVent BioPharma, Inc. stock, see the AVBP Stock Forecast page.
Spark’s Take on AVBP Stock
According to Spark, TipRanks’ AI Analyst, AVBP is a Underperform.
The overall score reflects the high-risk, high-reward nature of an early-stage biotechnology company like ArriVent BioPharma. While the company shows strong balance sheet stability and strategic pipeline expansion, the lack of current revenue, negative cash flows, and recent downward price trends weigh heavily on the score. Investors should consider the potential long-term benefits of the oncology pipeline expansion balanced against the typical risks associated with biotech investments.
To see Spark’s full report on AVBP stock, click here.
More about ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics to address unmet medical needs in cancer treatment. The company is advancing its lead candidate, firmonertinib, a mutation-selective EGFR inhibitor, and other novel therapeutics, such as next-generation antibody drug conjugates.
Average Trading Volume: 271,402
Technical Sentiment Signal: Buy
Current Market Cap: $862.8M
For an in-depth examination of AVBP stock, go to TipRanks’ Overview page.